GGrantIndex
Sort

50,496 grants matching lung cancer

miR-155 targeted therapeutics for precision medicine in lung cancer

$536,674
George A. Calin · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · CA

Chemical Methods for Ferrous Iron Dependent Drug Delivery

$536,653
Adam R Renslo · University Of California, San Francisco · R01 · FY2022 · AI

Chemical Methods for Ferrous Iron Dependent Drug Delivery

$536,653
Adam R Renslo · University Of California, San Francisco · R01 · FY2020 · AI

Chemical Methods for Ferrous Iron Dependent Drug Delivery

$536,653
Adam R Renslo · University Of California, San Francisco · R01 · FY2021 · AI

Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism

$536,641
Margaret C. Fang · University Of California, San Francisco · R01 · FY2014 · HL

Effect of Neonatal Hyperoxia on Alveolar Development and Infection

$536,581
Michael A O'Reilly · University Of Rochester · R01 · FY2021 · HL

Effect of Neonatal Hyperoxia on Alveolar Development and Infection

$536,581
Michael A O'Reilly · University Of Rochester · R01 · FY2020 · HL

Effect of Neonatal Hyperoxia on Alveolar Development and Infection

$536,581
Michael A O'Reilly · University Of Rochester · R01 · FY2019 · HL

Multigenic copy number alterations

$536,561
Scott Powers · State University New York Stony Brook · R01 · FY2019 · CA

University of Washington/Fred Hutch Center for AIDS Research

$536,547
Connie L Celum · University Of Washington · P30 · FY2024 · AI

Fractionated photoimmunotherapy to harness low-dose immunostimulation in ovarian cancer

$536,528
Bryan Quilty Spring · Northeastern University · U01 · FY2025 · CA

RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies

$536,497
Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2019 · CA

RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies

$536,497
Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2021 · CA

RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies

$536,497
Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2022 · CA

RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies

$536,497
Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2020 · CA

Immunologic Monitoring and Cellular Products Laboratory

$536,490
Lisa Helene Butterfield · University Of Pittsburgh At Pittsburgh · P30 · FY2015 · CA

UCLA Pulmonary and Critical Care Medicine Training Program

$536,332
Steven M. Dubinett · University Of California Los Angeles · T32 · FY2020 · HL

Deciphering the molecular control of intratumoral dendritic cells

$536,319
Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA

Deciphering the molecular control of intratumoral dendritic cells

$536,319
Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA

Targeting cancer stem cells in JAK2V617F induced neoplasm

$536,307
Shaoguang Li · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · CA

Targeting cancer stem cells in JAK2V617F induced neoplasm

$536,307
Shaoguang Li · Univ Of Massachusetts Med Sch Worcester · R01 · FY2020 · CA

Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system

$536,240
Deeann Wallis-Schultz · University Of Alabama At Birmingham · R01 · FY2023 · CA

Behavioral Science Core

$536,191
Alan S Wayne · Division Of Basic Sciences - Nci · ZIC · FY2012 · CA

Role of PI3Kgamma in Tumor Progression and Metastasis

$535,870
Judith A. Varner · University Of California, San Diego · R01 · FY2025 · CA

Role of PI3Kgamma in Tumor Progression and Metastasis

$535,870
Judith A. Varner · University Of California, San Diego · R01 · FY2023 · CA